BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Müller D. Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacol Ther 2015;154:57-66. [PMID: 26145167 DOI: 10.1016/j.pharmthera.2015.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci 2020;109:74-103. [PMID: 31173761 DOI: 10.1016/j.xphs.2019.05.031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
2 Neri D, Sondel PM. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 2016;40:96-102. [PMID: 27060634 DOI: 10.1016/j.coi.2016.03.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 10.7] [Reference Citation Analysis]
3 Moeini S, Saeidi M, Fotouhi F, Mondanizadeh M, Shirian S, Mohebi A, Gorji A, Ghaemi A. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine. Arch Virol 2017;162:333-46. [PMID: 27699512 DOI: 10.1007/s00705-016-3091-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Fercher C, Keshvari S, McGuckin MA, Barnard RT. Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins. Exp Biol Med (Maywood) 2018;243:166-83. [PMID: 29256259 DOI: 10.1177/1535370217748575] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
5 De Luca R, Neri D. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. Cancer Immunol Immunother 2018;67:1381-91. [PMID: 29971465 DOI: 10.1007/s00262-018-2194-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
6 Bonati L, Tang L. Cytokine engineering for targeted cancer immunotherapy. Curr Opin Chem Biol 2021;62:43-52. [PMID: 33684633 DOI: 10.1016/j.cbpa.2021.01.007] [Reference Citation Analysis]
7 Fellermeier-Kopf S, Gieseke F, Sahin U, Müller D, Pfizenmaier K, Kontermann RE. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. Oncoimmunology 2018;7:e1471442. [PMID: 30228940 DOI: 10.1080/2162402X.2018.1471442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Sapski S, Beha N, Kontermann R, Müller D. Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. Oncoimmunology 2017;6:e1361594. [PMID: 29209565 DOI: 10.1080/2162402X.2017.1361594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
9 Rosini E, Volpi NA, Ziffels B, Grimaldi A, Sacchi S, Neri D, Pollegioni L. An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin. Nanomedicine 2021;36:102424. [PMID: 34174417 DOI: 10.1016/j.nano.2021.102424] [Reference Citation Analysis]
10 Neri D. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity. Cancer Immunol Res 2019;7:348-54. [PMID: 30824549 DOI: 10.1158/2326-6066.CIR-18-0622] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
11 De Luca R, Soltermann A, Pretto F, Pemberton-Ross C, Pellegrini G, Wulhfard S, Neri D. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy. Mol Cancer Ther 2017;16:2442-51. [PMID: 28716814 DOI: 10.1158/1535-7163.MCT-17-0211] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
12 Siegemund M, Beha N, Müller D. Production, Purification, and Characterization of Antibody-TNF Superfamily Ligand Fusion Proteins. Methods Mol Biol 2018;1827:351-64. [PMID: 30196506 DOI: 10.1007/978-1-4939-8648-4_18] [Reference Citation Analysis]
13 Fellermeier S, Beha N, Meyer JE, Ring S, Bader S, Kontermann RE, Müller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology 2016;5:e1238540. [PMID: 27999756 DOI: 10.1080/2162402X.2016.1238540] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
14 Grinberg Y, Benhar I. Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins. Biomedicines 2017;5:E28. [PMID: 28574434 DOI: 10.3390/biomedicines5020028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Maia FR, Reis RL, Oliveira JM. Finding the perfect match between nanoparticles and microfluidics to respond to cancer challenges. Nanomedicine 2020;24:102139. [PMID: 31843662 DOI: 10.1016/j.nano.2019.102139] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]